Con­tineum says it will seek $136M in IPO to back its mid-stage neu­ro drug

Con­tineum Ther­a­peu­tics has set a price range for its up­com­ing IPO and plans to sell 8.8 mil­lion shares be­tween $16 and $18 apiece.

Its ex­pect­ed en­try on­to the mar­ket lat­er this week fol­lows fel­low San Diego biotech Bound­less Bio, and Con­tineum $CT­NM would raise about $136 mil­lion in its Nas­daq de­but, ac­cord­ing to a Mon­day se­cu­ri­ties fil­ing. In­cu­bat­ed by Ver­sant Ven­tures, the John­son & John­son-part­nered small mol­e­cule mak­er was pre­vi­ous­ly known as Pipeline Ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER